Press

MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial Results and Provide Business Update

Nov 3 • 1 min read

Mind Medicine Inc. (NASDAQ: MNMD | NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Thursday, November 10, 2022, at 8:30 a.m. EDT to discuss its financial results for the quarter ended September 30, 2022 and provide a business…

First Patient Dosed in Clairvoyant’s Phase 2 Clinical Trial Exploring Psilocybin as a Treatment for Alcohol Use Disorder

Nov 3 • 3 min read

Clairvoyant Therapeutics, a clinical stage biotech company focused on the development of psychedelic drug therapies for the treatment of addiction, is pleased to announce the first patient has been dosed in the company’s Phase 2 clinical trial investigating psilocybin for the treatment of alcohol use disorder (AUD). Clairvoyant’s randomized, controlled, clinical trial, CLA-PSY-201, will evaluate…

COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine

Nov 3 • 8 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that The New England Journal of Medicine (NEJM), the world’s leading peer-reviewed medical journal, has published the positive results from its phase 2b trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD) – the largest study…

Silo Wellness Breaking News: Jackson County Oregon’s Proposed TPM Restrictions Put Rural Psilocybin Retreat Therapy Centers at Risk

Nov 3 • 3 min read

Silo Wellness Inc. (CSE: SILO | OTCQB: SILFF | FSE: 3K7A), Oregon’s only publicly traded psychedelics company, announces that the Jackson County Planning Commission has proposed to amend the Jackson County Development Ordinance “to add Psilocybin Time, Place, and Manner Restrictions” (TPM) in the event that the BM 109 opt-out vote is unsuccessful next week. The…

Revitalist Releases Supplement Line to Enhance the Results of Psychedelic Medicines

Nov 2 • 2 min read

Revitalist Lifestyle and Wellness LTD. (CSE: CALM | OTCQB: RVLWF | FSE: 4DO), releases proprietary supplement lines to extend the results of psychedelic medicine outcomes. Through a proprietary blend of vitamins, anti-inflammatories and known cognitive enhancing ingredients, Revive+ and Restore+ have been formulated to enhance psychedelic therapy. “Providing a comprehensive wellness offering to our clients…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441